SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: george who wrote (420)10/31/1997 4:34:00 PM
From: Frank Buck  Read Replies (2) of 1894
 
George-

Here is a quote from AccuMed in one of their filings;

"If any company currently marketing rescreening products
receives FDA clearance or approval for use of its product as a primary screening system to replace or work in conjunction with conventional Pap smear screening or if automated analysis systems are developed and receive FDA clearance or approval, the use of conventional Pap smear screening could be substantially affected and the Company's business, financial condition and results of operations could be materially adversely affected."
End

An August 28, '97 press release by NeoPath (NPTH) a competitor of ACMI in the PAP Smear Detection Device arena states that they (NPTH) are seeking FDA Approval for Primary Screening of their
AutoPap screening system.

Question???

In light of this FDA application by NeoPath (for Primary Screening Status of their AutoPap system), what impact will this have on AccuMed's AcCell system if Primary Screening status is granted to NeoPath?

I would be really interested to hear what the response is, wouldn't you?

Frank Buck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News